Table 4.
Demographic and clinical differences at diagnosis and 8 years between patients without erosions (never erosive) and patients with no erosions at diagnosis but erosions at 1 year and/or later (later erosive)
| At diagnosis | At 8 years | |||||
|---|---|---|---|---|---|---|
| Never erosive mean (SD) | Later erosive mean (SD) | p value | Never erosive mean (SD) | Later erosive mean (SD | p value | |
| N (%) | 138 (42) | 190 (58) | 138 (42) | 190 (58) | ||
| Age, year | 52 (14) | 52 (12) | 0.982 | |||
| Gender, female, % | 67 | 74 | 0.168 | |||
| RF, % | 44 | 71 | < 0.001 | |||
| AntiCCP, % | 29 | 68 | < 0.001 | |||
| Seropos., % | 53 | 76 | < 0.001 | |||
| Never smoker, % | 45 | 43 | ||||
| Smoker, % | 21 | 29 | 0.214 | |||
| Previous smoker, % | 34 | 28 | ||||
| Duration, months | 7 (3) | 6 (3) | 0.187 | |||
| DAS28 | 4.92 (1.37) | 5.04 (1.24) | 0.405 | 2.86 (1.32) | 2.95 (1.32) | 0.572 |
| PhAss | ||||||
| No, % | 3 | 1 | 50 | 38 | ||
| Low, % | 24 | 23 | 0.543 | 43 | 48 | 0.087 |
| Moderate, % | 58 | 61 | 7 | 12 | ||
| High, % | 15 | 14 | 1 | 3 | ||
| SJC | 9 (6) | 9 (6) | 0.681 | 1 (3) | 2 (3) | 0.005 |
| TJC | 9 (7) | 8 (6) | 0.421 | 3 (5) | 2 (4) | 0.137 |
| PatGA | 45 (26) | 47 (25) | 0.549 | 30 (26) | 30 (25) | 0.832 |
| ESR | 26 (21) | 29 (21) | 0.223 | 14 (15) | 16 (13) | 0.311 |
| CRP | 23 (28) | 29 (25) | 0.137 | 6 (6) | 8 (12) | 0.066 |
| Pain | 45 (25) | 50 (23) | 0.071 | 30 (25) | 30 (24) | 0.927 |
| HAQ | 0.90 (0.66) | 0.98 (0.60) | 0.304 | 0.59 (0.55) | 0.55 (0.55) | 0.472 |
| ES | 0. | 0 | 0.241 | 0 | 7 (8) | < 0.001 |
| JSN | 0 (2) | 1 (3) | < 0.001 | 3 (5) | 15 (15) | < 0.001 |
| SHS | 0 (2) | 1 (3) | < 0.001 | 3 (5) | 22 (20) | < 0.001 |
| Treatment | ||||||
| No DMARD, % (Std.Res.) | 26 (1.1) | 18 (− 1.0) | 34 (2.4) | 17 (− 2.1) | ||
| cDMARD, % (Std.Res.) | 57 (− 1.2) | 71 (1.0) | 0.033 | 53 (− 1.2) | 66 (1.0) | < 0.001 |
| bDMARD, % (Std.Res.) | 0 | 0 | 5 (− 1.8) | 13 (1.5) | ||
| CS no DMARD, % (Std.Res.) | 17 (1.2) | 11 (− 1.0) | 8 (1.2) | 4 (− 1.0) | ||
RF rheumatoid factor, AntiCCP; anticyclic citrullinated peptides, Seropos. RF and/or antiCCP positive, DAS28 disease activity score of 28 joints, PhAss physician´s global assessment of disease activity, SJC swollen joint count, TJC tender joint count, PatGA patient global assessment, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ health assessment questioner, ES erosion score, JSN joint space narrowing, SHS Sharp van der Heijde score, DMARD disease modifying antirheumatic drugs, c conventional, b biological, CS corticosteroids